All In Biotech

Drug Trial Radar · NCT03918915

The Safety and Efficacy of SYD-101 in Children With Myopia

A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 852 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

852

Actual

Start

Apr 24, 2019

Primary completion

May 2, 2024

Study completion May 1, 2025

Sponsor

Lead sponsor
Sydnexis, Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.

Conditions

  • Nearsightedness
  • Near Sightedness
  • Near-sightedness

Interventions

  • SYD-101 0.01%Drug

    Sterile topical ophthalmic solution

  • SYD-101 0.03%Drug

    Sterile topical ophthalmic solution

  • VehicleDrug

    Sterile topical ophthalmic solution without active ingredient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myopic Progression <-0.75 D (Diopters)Time frame: Month 36

Locations

47 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 143

    Irwindale, California

  • Site 144

    Pasadena, California

  • Site 148

    San Diego, California

  • Site 104

    San Diego, California

  • Site 110

    Santa Barbara, California

  • Site 133

    Sunnyvale, California

  • Site 130

    Colorado Springs, Colorado

  • Site 100

    Fort Collins, Colorado

  • Site 102

    Danbury, Connecticut

  • Site 150

    Waterbury, Connecticut

  • Site 122

    Fort Lauderdale, Florida

  • Site 109

    Jupiter, Florida

  • Site 119

    Sweetwater, Florida

  • Site 120

    Tamarac, Florida

  • Site 124

    Marietta, Georgia

  • Site 116

    Chicago, Illinois

  • Site 106

    Wilmette, Illinois

  • Site 135

    Indianapolis, Indiana

  • Site 131

    Munster, Indiana

  • Site 137

    Pittsburg, Kansas

  • Site 138

    Bangor, Maine

  • Site 123

    Boston, Massachusetts

  • Site 114

    Washington, Missouri

  • Site 132

    Henderson, Nevada

  • Site 139

    Albuquerque, New Mexico

  • Site 127

    Buffalo, New York

  • Site 117

    Chapel Hill, North Carolina

  • Site 121

    Raleigh, North Carolina

  • Site 105

    Fargo, North Dakota

  • Site 111

    Medford, Oregon

  • Site 147

    Tigard, Oregon

  • Sie 136

    Bala-Cynwyd, Pennsylvania

  • Site 128

    Cranberry Township, Pennsylvania

  • Site 108

    Charleston, South Carolina

  • Site 126

    Lakeway, Texas

  • Site 142

    San Antonio, Texas

  • Site 101

    San Antonio, Texas

  • Site 115

    The Woodlands, Texas

  • Site 149

    Ogden, Utah

  • Site 140

    Ogden, Utah

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.